The meta-analysis published by Gill Schierhout and colleagues1 reported an increased relative risk of premature death in individuals infected with HTLV-1 compared with individuals not infected with HTLV-1 (RR 1·57, 95% CI ...

To the Editor—We read with interest the article by Patel and colleagues [1], which reported an unexpected 33% prevalence of anti–hepatitis delta virus antibodies (anti-HDV-Abs) in a large and representative US household ...

Medical and social attention to HIV infection has declined globally and is increasingly focused on developing regions, where the epidemic is still largely uncontrolled. In North America and western Europe, AIDS is rarely ...

Carta al editor

Background: HIV-1 and HIV-2 differ in their antiretroviral (ARV) susceptibilities and drug resistance mutations (DRMs). Methods: We analyzed published HIV-2 pol sequences to identify HIV-2 treatment-selected mutations ...

OBJECTIVE: To examine the clinical burden and disease spectrum, as well as time trends for human T-cell leukemia virus type 1 (HTLV-1) and HTLV type 2 (HTLV-2) hospital admissions. DESIGN: Retrospective, observational study ...

A relationship between the infecting dose and the risk of disease severity has not been demonstrated for SARS-CoV-2 infection. Here, we report three clusters of individuals that were potentially exposed to distinct inoculum ...

Nanoformulations of cabotegravir prodrugs have been developed to prolong the pharmacokinetics of the antiretroviral agent. They can be present in the plasma of mice and non-human primates for a year following a single injection.

Despite the availability of both effective preventive vaccines and oral antivirals, over 250 million people are chronically infected with the hepatitis B virus (HBV). Globally, chronic hepatitis B is the leading cause of ...

Background: The risk of transfusion-transmitted viral infections is very low in developed countries. Recent massive migration flows from highly hepatitis B virus (HBV), hepatitis C virus (HCV) and/or HIV endemic regions ...